Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ DR4 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA5144266
Description
DR4 Polyclonal Antibody for Western Blot, ICC/IF, IHC (P), IP, ELISA
TRAIL-R1 (CD261, DR4) is a type I transmembrane protein, also called TRAIL receptor 1. The ligand for this DR4 death receptor has been identified and termed TRAIL, which is a member of the TNF family. DR4, as many other receptors (Fas, TNFR1, etc.), mediates apoptosis and NF kappaB activation in many cells and tissues. Apoptosis, a programmed cell death, is a operating process in normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by coupled of certain cytokines (TNF family - TNF, Fas ligand) and their death domain containing receptors (TNFR1, Fas receptor).
Specifications
DR4 | |
Polyclonal | |
Unconjugated | |
TNFRSF10A | |
APO2; CD261; cytotoxic TRAIL receptor; death receptor 4; DR4; MGC9365; sCD261; soluble CD261; soluble TRAIL; sTRAIL; TNF receptor superfamily member 10a; TNF-related apoptosis-inducing ligand receptor 1; TNFRSF10A; TRAIL R1; TRAIL receptor 1; TRAILR1; TRAIL-R1; TRAILR-1; tumor necrosis factor receptor superfamily member 10A; tumor necrosis factor receptor superfamily member 10a variant 2; tumor necrosis factor receptor superfamily, member 10a | |
Rabbit | |
Protein G | |
RUO | |
8797 | |
-20°C or -80°C if preferred | |
Liquid |
ELISA, Immunohistochemistry (Paraffin), Immunoprecipitation, Western Blot, Immunocytochemistry | |
3.075 mg/mL | |
PBS with 50% glycerol and 0.03% Proclin 300; pH 7.4 | |
O00220 | |
TNFRSF10A | |
Recombinant Human Tumor necrosis factor receptor superfamily member 10A protein (263-468AA). | |
100 μg | |
Primary | |
Human | |
Antibody | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction